<DOC>
	<DOCNO>NCT02531867</DOCNO>
	<brief_summary>This multicenter study Japan . Eleven sit already participate investigator-initiated clinical study ( Early Access Program ) participate study.The objective study gain information safety efficacy treatment asfotase alfa .</brief_summary>
	<brief_title>Post-approval Clinical Study Asfotase Alfa Treatment Patients With Hypophosphatasia ( HPP ) Japan</brief_title>
	<detailed_description />
	<mesh_term>Hypophosphatasia</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Patient parent ( legal guardian ) must provide write informed consent prior performance studyrelated procedure must willing comply study procedure . Where appropriate require local regulation , patient assent participation must also obtain . 2 . Patient complete investigatorinitiated clinical study ( HPPJEAP01 ) protocol asfotase alfa 1 . Patient document form rickets cause condition HPP , include , limited , rickets cause 25 ( OH ) vitamin D deficiency 2 . Patient serum calcium and/or phosphorus level normal range 3 . Patient pregnant lactate 4 . Patient receive treatment bisphosphonates within 2 year prior Screening visit 5 . Patient document sensitivity component asfotase alfa 6 . Patient currently enrol program clinical study involve investigational new drug , device , treatment HPP ( eg , bone marrow transplantation ) 7 . Patient clinically significant disease opinion Investigator , define non HPPrelated condition patient consider medically unstable .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HPP</keyword>
	<keyword>Bone Disease</keyword>
	<keyword>Soft Bones</keyword>
	<keyword>Low Alkaline Phosphatase</keyword>
	<keyword>Genetic Metabolic Disorder</keyword>
	<keyword>Alkaline Phosphatase</keyword>
	<keyword>Rickets</keyword>
	<keyword>Osteomalacia</keyword>
</DOC>